Reshaping the HIV treatment and prevention landscape
Blenrep: first-in-class BCMA treatment for
patients with multiple myeloma
Significant unmet medical need
- Multiple myeloma is the 2nd most common haematological
malignancy with >175K pts/yr global incidence2
gsk
Significant opportunity to move in to 2L+ with
compelling efficacy and the ability to reduce dose
Phase 1/2 ALGONQUIN study³ (Blenrep plus PomDex)
Response rates (%) by dose
Differentiated asset with broad development
programme
-
-
Pivotal DREAMM-2 demonstrated deep
and durable responses as single agent
Easy outpatient administration and scalable
manufacturing compared to competitors
Corneal AEs (%) by dose
100%
ORR:95%
>VGPR:74%
100%
ORR:82%
>VGPR:64%
80%
21%
80%
18%
60%
60%
47%
40%
40%
64%
70%
20%
20%
26%
25%
17%
15%
0%
0%
1.92 mg/kg n=11
2.5mg/kg
Combined n=19
1.92 mg/kg n=12
2.5mg/kg
Combined n=20
CR VGPR PR
Visual Acuity Change*
G3/4 Keratopathy
Ongoing registrational studies in 2L
DREAMM-7 & DREAMM-8
1. CA: A Cancer Journal for Clinicians, Vol. 70, Issue 1, Han/Feb 2020 Pages 7-30, 2. Globocan 2020 Multiple Myeloma Fact Sheet, 3. Trudel, et al ASH 2020; Combined-2.5mg/kg include single, loading and split doses;
*Keratopathy by exam finding, visual acuity change 20/50 or worse in better seeing eye
90
90View entire presentation